Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hazra Website

Rohan Hazra, M.D.

Portait Photo of Rohan Hazra
HIV and AIDS Malignancy Branch
Adjunct Staff Clinician
Center for Cancer Research
National Cancer Institute
Building 6100, Room 4B11
6100 Executive Blvd.
Bethesda, MD 20892-7510
Phone:  
301-435-6868
Fax:  
Fax Number not listed
E-Mail:  
hazrar@mail.nih.gov

Biography

Dr. Hazra received his B.S. degree in biology from Yale University and his M.D. from the Johns Hopkins University School of Medicine. Following graduation from medical school, he completed a pediatric residency and pediatric infectious disease fellowship at Children's Hospital in Boston. While there he worked in the laboratory of Dr. Robert Husson on mycobacterial gene regulation and the molecular epidemiology of nontuberculous mycobacterial disease in children. In 2000, he joined the HIV and AIDS Malignancy Branch where he has been conducting clinical studies in pediatric HIV. Since 2007, he has maintained an adjunct position with the branch while working as a medical officer in the Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development. There, he oversees the Pediatric HIV AIDS Cohort Study (PHACS), a multicenter United States-based program that follows both perinatally HIV-infected youth and HIV-exposed/uninfected infants, children, and youth. In addition, he is actively involved in observational studies of perinatally HIV-infected children in Latin America and in clinical trials and other observational studies in the United States and globally. He is Board-Certified in both pediatrics and pediatric infectious diseases.

Research

Dr. Hazra's research interests include studying the long-term impact of HIV and its treatment on children, adolescents, and young adults who were infected with HIV as infants. In addition he continues to be involved in studies evaluating new antiretroviral medications and treatment strategies in HIV-infected children, especially in resource limited countries.

This page was last updated on 3/10/2014.